Evidence map›Paper›PMID 29725328›Full record

ReviewFrontiers in immunology2018

Role of TNF-TNF Receptor 2 Signal in Regulatory T Cells and Its Therapeutic Implications.

Sujuan Yang, Julie Wang, David Douglass Brand, Song Guo Zheng

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 234 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
234citing papers in PubMed, 4 pooled it
13.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

234 citing papers in PubMed, 4 syntheses or guidelines pooled it, 391 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Current landscape of drug induced retinal vasculitis.Journal of ophthalmic inflammation and infection · 2026
    Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Upregulation of TNFR2 Precedes TOX Expression by Exhausted T cells and Restricts Antitumor and Antiviral Immunity.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  17. Review
  18. Article
  19. Advancing therapeutic frontiers: a pipeline of novel drugs for UC management.Frontiers in gastroenterology (Lausanne, Switzerland) · 2026
    Review
  20. Review

174 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Sujuan YangDepartment of Clinical Immunology, Third Hospital at Sun Yat-sen University, Guangzhou, China.
Julie WangDivision of Rheumatology, Milton S. Hershey Medical Center at Penn State University, Hershey, PA, United States.
David Douglass BrandResearch Service, Memphis VA Medical Center, Memphis, TN, United States.
Song Guo ZhengDivision of Rheumatology, Milton S. Hershey Medical Center at Penn State University, Hershey, PA, United States.
Penn State Milton S. Hershey Medical Center · USMemphis VA Medical Center · USThird Affiliated Hospital of Sun Yat-sen University · CN

Funding

Therapeutic immunoregulation mediated by TGF-??-induced iTregs in autoimmune arthR01AR059103 · NIAMS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI JARJOUR, WAEL N · 2010 to 2020
$3.9M
Regulatory Mechanisms in Autoimmune ArthritisI01BX001193 · VA · MEMPHIS VA MEDICAL CENTER · PI BRAND, DAVID D. · 2013 to 2016
–
BLRD VA I01 BX001193NIAMS NIH HHS R01 AR059103
6 · The paper itself

Abstract

Tumor necrosis factor α (TNFα) is a pleiotropic cytokine which signals through TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2). Emerging evidence has demonstrated that TNFR1 is ubiquitously expressed on almost all cells, while TNFR2 exhibits a limited expression, predominantly on regulatory T cells (Tregs). In addition, the signaling pathway by sTNF

Indexed as

AnimalsAutoimmune DiseasesHumansReceptors, Tumor Necrosis Factor, Type IReceptors, Tumor Necrosis Factor, Type IISignal TransductionT-Lymphocytes, RegulatoryTumor Necrosis Factor-alphaReceptors, Tumor Necrosis Factor, Type IReceptors, Tumor Necrosis Factor, Type IITumor Necrosis Factor-alphaautoimmune diseasesregulatory T cellstumor necrosis factor receptor 1tumor necrosis factor receptor 2tumor necrosis factor α

Identifiers

PMID29725328
PMCPMC5916970
OpenAlexW2800399031

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.